Table V.
Functional and structural avidities of the A2/MART1 TCRs
| Clone | Donor | aAPC used for stimulation | TRBV | CDR3β | TRBJ | Functional avidity* without CD8 | Functional avidity with CD8 | Structural avidity† without CD8 | Structural avidity with CD8 |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| EC50 (μM) | EC50 (μM) | EC50 (μg/ml) | EC50 (μg/ml) | ||||||
| Cl.794 | #3 (A2−) | Mut-aAPC | 27 | CASSLLGDYGYTF | 1-2 | 0.12 | 0.16 | 0.06 | 0.02 |
| Cl.830 | #3 (A2−) | Mut-aAPC | 27 | CASSLGGAYEQYF | 2-7 | 0.13 | 0.14 | 0.01 | 0.006 |
| Cl.1599 | #1 (A2+) | Mut-aAPC | 27 | CASSFLGAMAEAFF | 1-1 | 0.14 | 0.16 | 0.06 | 0.02 |
| Cl.1606 | #1 (A2+) | Mut-aAPC | 27 | CASSLLGSYEQYF | 2-7 | 0.16 | 0.12 | 0.01 | 0.006 |
| Cl.1574 | #1 (A2+) | Mut-aAPC | 27 | CASSPWERINTEAFF | 1-1 | 0.35 | 0.15 | 0.1 | 0.03 |
| Cl.1593 | #1 (A2+) | Mut-aAPC | 27 | CASGNNQPQHF | 1-5 | 0.44 | 0.14 | 0.01 | 0.006 |
| DMF5‡ | 6-4 | CASSLSFGTEAFF | 1-1 | 1.4 | 0.33 | 0.03 | 0.02 | ||
| Cl.758 | #3 (A2−) | Wt-aAPC | 27 | CASSPRLAGDGELFF | 2-2 | 1.6 | 0.46 | 2.7 | 0.06 |
| Cl.1086 | #3 (A2−) | Wt-aAPC | 27 | CASSLHGPGGYTF | 1-2 | 2.4 | 0.63 | 0.04 | 0.01 |
| Cl.788 | #3 (A2−) | Wt-aAPC | 27 | CASGPSYEQYF | 2-7 | 2.9 | 0.57 | 0.05 | 0.01 |
| Cl.523 | #3 (A2−) | Wt-aAPC | 27 | CASGSYEQYF | 2-7 | n.m | 2.7 | n.m | 0.3 |
| Cl.413 | #1 (A2+) | Wt-aAPC | 27 | CASSVFGGDMGEKLFF | 1-4 | n.m | 10 | n.m | n.m |
n.m, not measurable.
*
Functional avidity, expressed as EC50 in μM, was defined as the concentration of peptide required to achieve 50% of maximal response.
†
Structural avidity, expressed as EC50 in μg/ml, was defined as the concentration of A2/MART1 multimer required to achieve half maximal multimer staining.